The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
PURPOSE: The relationship between prostate-specific antigen (PSA) level and prostate cancer risk remains subject to fundamental disagreements. We hypothesized that the risk of prostate cancer on biopsy for a given PSA level is affected by identifiable characteristics of the cohort under study. EXPER...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|
| _version_ | 1797072122912178176 |
|---|---|
| author | Vickers, A Cronin, A Roobol, M Hugosson, J Jones, J Kattan, M Klein, E Hamdy, F Neal, D Donovan, J Parekh, D Ankerst, D Bartsch, G Klocker, H Horninger, W Benchikh, A Salama, G Villers, A Freedland, S Moreira, D Schröder, F Lilja, H |
| author_facet | Vickers, A Cronin, A Roobol, M Hugosson, J Jones, J Kattan, M Klein, E Hamdy, F Neal, D Donovan, J Parekh, D Ankerst, D Bartsch, G Klocker, H Horninger, W Benchikh, A Salama, G Villers, A Freedland, S Moreira, D Schröder, F Lilja, H |
| author_sort | Vickers, A |
| collection | OXFORD |
| description | PURPOSE: The relationship between prostate-specific antigen (PSA) level and prostate cancer risk remains subject to fundamental disagreements. We hypothesized that the risk of prostate cancer on biopsy for a given PSA level is affected by identifiable characteristics of the cohort under study. EXPERIMENTAL DESIGN: We used data from five European and three U.S. cohorts of men undergoing biopsy for prostate cancer; six were population-based studies and two were clinical cohorts. The association between PSA and prostate cancer was calculated separately for each cohort using locally weighted scatterplot smoothing. RESULTS: The final data set included 25,772 biopsies and 8,503 cancers. There were gross disparities between cohorts with respect to both the prostate cancer risk at a given PSA level and the shape of the risk curve. These disparities were associated with identifiable differences between cohorts: for a given PSA level, a greater number of biopsy cores increased the risk of cancer (odds ratio for >6- versus 6-core biopsy, 1.35; 95% confidence interval, 1.18-1.54; P < 0.0005); recent screening led to a smaller increase in risk per unit change in PSA (P = 0.001 for interaction term) and U.S. cohorts had higher risk than the European cohorts (2.14; 95% confidence interval, 1.99-2.30; P < 0.0005). CONCLUSIONS: Our results suggest that the relationship between PSA and risk of a positive prostate biopsy varies, both in terms of the probability of prostate cancer at a given PSA value and the shape of the risk curve. This poses challenges to the use of PSA-driven algorithms to determine whether biopsy is indicated. |
| first_indexed | 2024-03-06T23:03:07Z |
| format | Journal article |
| id | oxford-uuid:62dd8af9-0ac9-4855-a78b-b58c4db3fd9a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:03:07Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:62dd8af9-0ac9-4855-a78b-b58c4db3fd9a2022-03-26T18:09:02ZThe relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:62dd8af9-0ac9-4855-a78b-b58c4db3fd9aEnglishSymplectic Elements at Oxford2010Vickers, ACronin, ARoobol, MHugosson, JJones, JKattan, MKlein, EHamdy, FNeal, DDonovan, JParekh, DAnkerst, DBartsch, GKlocker, HHorninger, WBenchikh, ASalama, GVillers, AFreedland, SMoreira, DSchröder, FLilja, HPURPOSE: The relationship between prostate-specific antigen (PSA) level and prostate cancer risk remains subject to fundamental disagreements. We hypothesized that the risk of prostate cancer on biopsy for a given PSA level is affected by identifiable characteristics of the cohort under study. EXPERIMENTAL DESIGN: We used data from five European and three U.S. cohorts of men undergoing biopsy for prostate cancer; six were population-based studies and two were clinical cohorts. The association between PSA and prostate cancer was calculated separately for each cohort using locally weighted scatterplot smoothing. RESULTS: The final data set included 25,772 biopsies and 8,503 cancers. There were gross disparities between cohorts with respect to both the prostate cancer risk at a given PSA level and the shape of the risk curve. These disparities were associated with identifiable differences between cohorts: for a given PSA level, a greater number of biopsy cores increased the risk of cancer (odds ratio for >6- versus 6-core biopsy, 1.35; 95% confidence interval, 1.18-1.54; P < 0.0005); recent screening led to a smaller increase in risk per unit change in PSA (P = 0.001 for interaction term) and U.S. cohorts had higher risk than the European cohorts (2.14; 95% confidence interval, 1.99-2.30; P < 0.0005). CONCLUSIONS: Our results suggest that the relationship between PSA and risk of a positive prostate biopsy varies, both in terms of the probability of prostate cancer at a given PSA value and the shape of the risk curve. This poses challenges to the use of PSA-driven algorithms to determine whether biopsy is indicated. |
| spellingShingle | Vickers, A Cronin, A Roobol, M Hugosson, J Jones, J Kattan, M Klein, E Hamdy, F Neal, D Donovan, J Parekh, D Ankerst, D Bartsch, G Klocker, H Horninger, W Benchikh, A Salama, G Villers, A Freedland, S Moreira, D Schröder, F Lilja, H The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. |
| title | The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. |
| title_full | The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. |
| title_fullStr | The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. |
| title_full_unstemmed | The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. |
| title_short | The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. |
| title_sort | relationship between prostate specific antigen and prostate cancer risk the prostate biopsy collaborative group |
| work_keys_str_mv | AT vickersa therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT cronina therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT roobolm therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT hugossonj therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT jonesj therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT kattanm therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT kleine therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT hamdyf therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT neald therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT donovanj therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT parekhd therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT ankerstd therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT bartschg therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT klockerh therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT horningerw therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT benchikha therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT salamag therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT villersa therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT freedlands therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT moreirad therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT schroderf therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT liljah therelationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT vickersa relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT cronina relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT roobolm relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT hugossonj relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT jonesj relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT kattanm relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT kleine relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT hamdyf relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT neald relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT donovanj relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT parekhd relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT ankerstd relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT bartschg relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT klockerh relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT horningerw relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT benchikha relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT salamag relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT villersa relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT freedlands relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT moreirad relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT schroderf relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup AT liljah relationshipbetweenprostatespecificantigenandprostatecancerrisktheprostatebiopsycollaborativegroup |